Form 4: Twist Bioscience Officer Sells Shares for Tax Obligations
Insider Transaction Report
A Twist Bioscience executive sold 269 shares of common stock at $25.76 per share to cover tax withholding obligations related to vested Restricted Stock Units.
Summary
- Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a transaction on September 8, 2025.
- Cho disposed of 269 shares of common stock at a price of $25.76 per share.
- The sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units.
- This transaction was not a discretionary trade by the reporting person.
- Following the reported transaction, Dennis Cho beneficially owns 103,037 shares of common stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is neutral in sentiment. It does not indicate a positive or negative outlook on the company's performance or stock price.
Future Outlook
The filing does not contain any forward-looking statements or guidance.
Industry Context
This transaction is a routine insider filing for tax-related stock sales, common across all industries for executives receiving equity compensation. It does not reflect broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a small, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or a significant shift in ownership.
Key Dates
| Date | Description |
|---|---|
| 09/08/2025 | Date of transaction where shares were disposed of. |
| 09/10/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThe filing details a routine, non-discretionary 'sell to cover' transaction by an executive to satisfy tax obligations on vested equity. This type of transaction is a standard part of executive compensation and does not reflect a discretionary decision to sell based on company performance or outlook. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as this event is neutral.
Keywords
Twist Bioscience, TWST, Form 4, Insider Transaction, Stock Sale, Sell to Cover, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.